| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
SpyGlass Pharma, Inc.
13D/A
Amendment 1
SGP · 85220G109
|
8.9% |
11/18/2026
Event 11/16/2026
|
|||
| Vensana Capital I GP, LLC | 8.9% | ||||
| Vensana Capital I, L.P. | 8.9% | ||||
| Kirk Nielsen | 8.9% | ||||
| Peter Justin Klein | 8.9% | ||||
|
SpyGlass Pharma, Inc.
13D
SGP · 85220G109
|
9.9% |
2/10/2026
Event 2/9/2026
|
|||
| Vensana Capital I GP, LLC | 9.9% | ||||
| Vensana Capital I, L.P. | 9.9% | ||||
| Kirk Nielsen | 9.9% | ||||
| Peter Justin Klein | 9.9% | ||||
|
CVRx, Inc.
13G/A
Amendment 3
CVRX · 126638105
|
7.2% |
2/6/2025
Event 12/31/2024
|
|||
| Vensana Capital I GP, LLC | 7.1% | ||||
| Vensana Capital I, L.P. | 7.1% | ||||
| Kirk Nielsen | 7.2% | ||||
| Peter Justin Klein | 7.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.